Harry Palmin
2019
In 2019, Harry Palmin earned a total compensation of $844.4K as Chief Operating Officer and Chief Financial Officer at Opexa Therapeutics, a 97% increase compared to previous year.
Compensation breakdown
| Option Awards | $462,041 |
|---|---|
| Salary | $382,400 |
| Total | $844,441 |
Palmin received $462K in option awards, accounting for 55% of the total pay in 2019.
Palmin also received $382.4K in salary.
Rankings
In 2019, Harry Palmin's compensation ranked 10,009th out of 13,971 executives tracked by ExecPay. In other words, Palmin earned more than 28.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,009 out of 13,971 | 28th |
Division Manufacturing | 4,042 out of 5,695 | 29th |
Major group Chemicals And Allied Products | 1,533 out of 2,194 | 30th |
Industry group Drugs | 1,311 out of 1,880 | 30th |
Industry Pharmaceutical Preparations | 975 out of 1,392 | 30th |
Source: SEC filing on October 14, 2020.
Palmin's colleagues
We found two more compensation records of executives who worked with Harry Palmin at Opexa Therapeutics in 2019.
News
Opexa Therapeutics CEO Chris Schelling's 2022 pay jumps 51% to $834K
April 14, 2023
Opexa Therapeutics Chief Business Officer Jefferson Davis receives $635K in 2021
April 15, 2022
Opexa Therapeutics CEO Chris Schelling's 2020 pay falls 54% to $676K
April 16, 2021
Opexa Therapeutics CEO Chris Schelling's 2019 pay jumps 167% to $1.5M
October 14, 2020
Opexa Therapeutics CEO Chris Schelling's 2018 pay slips 6% to $550K
April 12, 2019